Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NADINA stage III melanoma trial
NL-OMON60377Phase 3Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ipilimumab, nivolumab, dabrafenib + trametinib and trametinib in melanoma (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Event-free survival. Started Jul 2021; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON60377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60377.